

PROGRESSION-FREE SURVIVAL AND BIOMARKER CORRELATES OF RESPONSE WITH BEMPEG PLUS NIVO IN PREVIOUSLY UNTREATED PATIENTS WITH METASTATIC MELANOMA: RESULTS FROM THE PIVOT-02 STUDY

¹Adi Diab*, ²Scott Tykodi, ³Gregory Daniels, ⁴Michele Maio, ⁵Brendan Curti, ⁶Karl Lewis, ⁷Sekwon Jang, ⁸Ewa Kalinka, ⁹Igor Puzanov, ¹⁰Alexander Spira, ¹¹Daniel Cho, ¹²Shanhong Guan, ¹²Erika Puente, ¹²Ute Hoch, ¹²Sue Currie, ¹²Tuan Nguyen, ¹²Wei Lin, ¹²Mary Tagliaferri, ¹²Jonathan Zalevsky, ¹³Mario Sznol, ¹³Michael Hurwitz. ¹The University of Texas MD Anderson Cancer Center, Houston, TX, USA; ²University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA, USA; ³University of California, La Jolla, CA, USA; ⁴Azienda Ospedaliera Universitaria Senese, Siena, Italy; ⁵Providence Cancer Center and Earle A. Chiles Research Institute, Portland, OR, USA; ⁶University of Colorado, Aurora, CO, USA; ⁷Inova Fairfax Hospital, Fairfax, VA, USA; ⁸Santa Familia Medical Institute, Lodz, Poland; ⁹Roswell Park Cancer Institute, Buffalo, NY, USA; ¹⁰Virginia Cancer Specialists, Fairfax, VA, USA; ¹¹NYU Medical Oncology Associates, New York, NY, USA; ¹²Nektar Therapeutics, San Francisco, CA, USA; ¹³Yale School of Medicine, New Haven, CT, USA

Background An unmet need exists for novel therapies that produce deep and durable responses in more patients with metastatic melanoma (metMEL). Encouraging clinical activity was observed with the CD122-preferential IL-2 pathway agonist bempedalesleukin (BEMPEG) plus nivolumab (NIVO) in first-line metMEL in the phase 1/2 PIVOT-02 trial (NCT02983045),¹ leading to FDA Breakthrough Therapy Designation. We present updated clinical results from PIVOT-02 in first-line metMEL, and biomarkers of response.

Methods 41 patients with previously untreated stage IV melanoma (known PD-L1 status by immunohistochemistry; 28–8 PharmDx) received ≥ 1 dose of BEMPEG (0.006 mg/kg) plus NIVO (360 mg) q3wks; 38 patients were efficacy-evaluable (≥ 1 post-baseline tumor scan). Primary endpoints were safety and objective response rate (ORR; RECIST v1.1; BICR); other endpoints included PFS, OS and biomarkers. Polyfunctional strength index (PSI) of circulating lymphocytes (determined using single-cell cytokine analysis [Isoplexis]) and eosinophil count (determined from hematology analysis) at baseline and Cycle1-Day8 were analyzed using the median cut-off for correlations with ORR and PFS. Biomarkers, including CD8⁺ tumor infiltrating lymphocytes (TIL) and interferon-gamma (IFN γ) gene expression profile (GEP), were measured in baseline tumor biopsies and analyzed for correlation with ORR and PFS.

Results At median follow-up of 25.7 months (15May2020), ORR by BICR was 53% (20/38 patients). Complete response occurred in 13/38 patients (34%): 23% PD-L1-negative (<1% tumor cell expression); 41% PD-L1-positive (≥ 1 % tumor cell expression). Further deepening of response was observed, with 17/38 patients (45%) achieving 100% reduction in target lesions and a 79% median reduction from baseline in tumor size (previously 62%).¹ Median time to response and time to complete response was 2.0 and 7.9 months, respectively. Median PFS and OS were not reached. 2-year OS rate was 77% (95% CI: 60–87; ITT). Safety was consistent with previous reports.¹ IFN γ GEP and CD8⁺ TIL in baseline tumor biopsies were significantly associated with ORR and PFS. Analysis of Cycle1-Day8 blood samples demonstrated significant increases in CD4⁺PSI, CD8⁺PSI, and eosinophils from baseline. Increased CD8⁺PSI was significantly associated with higher ORR and PFS; increased eosinophils were significantly associated with higher ORR.

Conclusions BEMPEG plus NIVO was well tolerated in first-line metMEL, with durable and further deepening of responses, regardless of baseline PD-L1 status. At 25.7 months' follow-up, mPFS and mOS were not reached. Early on-treatment (Day8) increases in CD8⁺PSI and eosinophils in blood were identified as non-invasive biomarkers of response that are detectable well before clinical measures of response. A phase 3 trial evaluating BEMPEG plus NIVO in first-line metMEL is enrolling (NCT03635983).

Trial Registration NCT02983045

Ethics Approval The study was approved by the institutional review board of each participating site.

REFERENCE

1. Diab A, Puzanov I, Maio M, et al. Clinical activity of BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: updated results from the phase 1/2 PIVOT-02 study. Oral presentation at SITC; November 6–10, 2019; National Harbor, MD, USA. Abstract #035.

<http://dx.doi.org/10.1136/jitc-2020-SITC2020.0420>

INITIAL RESULTS OF A PHASE 1 TRIAL OF RP2, A FIRST IN CLASS, ENHANCED POTENCY, ANTI-CTLA-4 ANTIBODY EXPRESSING, ONCOLYTIC HSV AS SINGLE AGENT AND COMBINED WITH NIVOLUMAB IN PATIENTS WITH SOLID TUMORS

¹Francesca Aroldi, ²Joseph Sacco, ³Kevin Harrington, ²Anna Olsson-Brown, ³Pablo Nandares, ⁴Lavita Menezes, ⁴Praveen Bommarreddy, ⁴Suzanne Thomas, ⁵Howard Kaufman, ⁴Selda Samakoglu, ⁴Robert Coffin, ¹Mark Middleton*. ¹University of Oxford, Oxford, UK; ²University of Liverpool, Wirral, UK; ³The Institute of Cancer Research, London, UK; ⁴Replimune Inc., Woburn, MA, USA; ⁵Massachusetts General Hospital, Cambridge, MA, USA

Background RP2 is an enhanced potency oncolytic HSV-1 expressing granulocyte-macrophage colony-stimulating factor (GM-CSF), a fusogenic protein (GALV-GP R-), and an anti-cytotoxic T lymphocyte antigen 4 (CTLA-4) antibody-like molecule which is being tested in an open-label, multicenter, phase 1 study alone and combined with PD-1 blockade (NCT04336241).

Methods The objectives were to assess initial safety and efficacy and determine the recommended phase 2 dose (RP2D) of RP2 alone and combined with nivolumab. Patients were to be treated using a 3+3 dose escalation at two dose levels of up to 10 mL of RP2 Q2W up to 5 times (dose level 1: 10⁵ PFU/mL then 4 doses of 10⁶ PFU/mL; dose level 2: 10⁶ PFU/mL then 4 doses of 10⁷ PFU/mL). Following determination of the RP2D, additional HSV-1 seronegative patients were to be enrolled such that ≥ 3 had been dosed with RP2 at the RP2D, and a combination cohort of up to 30 patients dosed up to 8 times with RP2 at the RP2D combined with nivolumab (240 mg Q2W for 4 months from the second RP2 dose, then 480 mg Q4W for 20 months) opened. Lesions were injected directly or under imaging guidance used for visceral lesions. Tumor biopsies were obtained for biomarker analysis. Viral shedding and anti-HSV antibody titers were also monitored.

Results Six HSV seropositive patients were enrolled in the dose-escalation phase with primarily Grade 1–2 adverse events, including febrile and other constitutional symptoms, local inflammation, and erythema observed. There were no DLTs requiring dose level expansion. The RP2D was selected as up to 10 mL of 10⁶ PFU/mL followed Q2W by multiple doses